Abstract
Isocitrate dehydrogenase (IDH1) is an NADP-dependent enzyme that catalyzes the decarboxylation of isocitrate to alpha-ketoglutarate. The IDH1-R132H mutation predicts a better clinical outcome for glioma patients, and the expression of IDH1-R132H correlates with a favorable outcome in patients with brain tumors. Here, we investigated IDH1-R132H expression in both gastric (n=526) and colorectal (n=399) tissues by performing immunohistochemistry analyses on tissue microarrays. We also tested whether IDH1-R132H expression correlated with various clinical parameters. In both gastric and colorectal cancer, expression of IDH1-R132H was associated with tumor stage. Patients with low IDH1-R132H expression had a poor overall survival. Our data indicate that IDH1-R132H expression could be used as a predictive marker of prognosis for patients with gastrointestinal cancer.
Highlights
Gastric cancer is the third leading cause of death from malignancy worldwide [1]
IDH1 is a NADP-dependent enzyme that catalyzes the decarboxylation of isocitrate into alpha-ketoglutarate and provides the needed cytosolic NADPH [21, 26]
We examined IDH1-R132H expression in gastrointestinal cancers by immunohistochemistry in human tissue
Summary
Gastric cancer is the third leading cause of death from malignancy worldwide [1]. In China GC is the third leading cause of cancer-related deaths, affecting 32 per every 100,000 males and 13 per every 100,000 females [7]. Colorectal cancer (CRC) is the third most common tumor among men and the second among women [8]. The morbidity of CRC is generally lower in Asia than in the Western world [9, 10], the incidence of colon cancer continues to increase in China [11]. CRC is the fifth most common cause of cancer-related deaths, affecting 14 per every 100,000 people in China [12, 13]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
